13th Annual BEAR Cage Competition

The ATS Drug Device Discovery and Development (DDDD) Committee invites you to apply to the 13th Annual BEAR Cage (Building Education to Advance Research) competition by Feb. 8, 2027 deadline.
The top three submissions chosen by the DDDD Committee will pitch their highly innovative research proposals to a panel of translational science experts representing academia, industry, and governmental sectors in front of a live audience at the ATS International Conference in May 2027 in New Orleans.
The panel, with audience participation, will “vet” these proposals with each presenter, providing a unique “shark-tank”-like learning environment that fuels real-time feedback and propels the strategic thinking required for these novel ideas to become innovations. After each presentation, the live panel and audience will have sufficient time to ask questions of each of the top three contestants.
Ultimately, the panel will award one grand prize winner a $10,000 prize and the two runner-up proposals $2,500 each.
**You will need to enter your ATS login information on the first page to get into the portal. If you do not already have an ATS login, you can create one on the login page.
For any questions about the application process or the competition for ATS 2027, please send an email to dddd@thoracic.org.
ATS 2026 BEAR Cage Finalists
The 2026 BEAR Cage event was well received and attended. Congratulations to 2026 BEAR Cage winner Emily Mitchell, MD, and the other finalists, all receiving cash prizes as well as mentorship for the next year.

Emily Mitchell, MD
Co-Investigator
University of California, San Diego
“Breaking the Silence: Eye-Tracking for Restoring Patient Agency and Communication in the ICU"

Emily Mitchell, MD presenting her winning proposal at the 2026 BEAR Cage

Xiang Gao, PhD
Chief Scientist
Scientific Horizons Consulting
“A Precision Intranasal Nebulization Platform (PIN) for Targeted Nasal Drug Delivery”

Keziyah Yisrael-Gayle, PhD
Postdoctoral Fellow/Founder and CEO
TollRAir/UC-Riverside
“Development of an Extended-Release Aerosol Formulation of Toll-like Receptor 4 (TLR4) Inhibitors to Protect Against Lipopolysaccharide-Induced Non-Allergic Asthma”